Year

2015
2,000L Demonstration Batch Completed at Lonza, Houston FacilitySAN DIEGO, Jan. 5, 2015 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it has conducted initial scale up of its viral manufacturing process for MYDICAR (AAV1/SERCA2a) to commercial scale.
SAN DIEGO, Dec. 16, 2014 (GLOBE NEWSWIRE) -- Celladon Corporation (Nasdaq:CLDN), a clinical-stage biotechnology company with industry-leading expertise in the development of cardiovascular gene therapy, today announced that it has been added to the NASDAQ Biotechnology Index, through the annual update that will become effective prior to market open on Monday, December 22, 2014.The NASDAQ...
1 10 11 12

Nyheder

Lundbeckfonden vil dække universiteters projektrelaterede indirekte omkostninger
10. december 2018
Danske forskere: Patientforsøg med stamceller mod diabetes nærmer sig
10. december 2018
Professor søges!
5. december 2018

Lundbeckfonden

Lundbeckfonden Ventures

Lundbeckfonden Emerge